Celldex Therapeutics CLDX
NASDAQ CLDX
$39.56 +0.19 (+0.50%)
As of: Sep 4, 2026 · 3:12 PM EDT

Celldex Therapeutics (CLDX) Long-Term Debt Repayments (2011)

Celldex Therapeutics (CLDX) posted quarterly Long-Term Debt Repayments of $12.5 million for Q1 2011.

Analysis

Celldex Therapeutics (CLDX) Long-Term Debt Repayments (2011) Analysis & Trends

Celldex Therapeutics' Long-Term Debt Repayments history runs 1 years deep, the most recent figure standing at $12.5 million for Q1 2011.

  • In Q1 2011, Long-Term Debt Repayments changed N/A year-over-year to $12.5 million; the TTM figure through Dec 2011 stood at $12.5 million (changed N/A YoY), while the FY2011 annual figure was $12.5 million, changed N/A from the prior year.
  • Long-Term Debt Repayments for Q1 2011 stood at $12.5 million.
  • The five-year high for Long-Term Debt Repayments was $12.5 million in Q1 2011, with the low at $12.5 million in Q1 2011.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Vertex Pharmaceuticals 138.51 Bn 130.66 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.24 Bn 77.25 Bn 3.93 Bn -
3 Argenx Se 63.46 Bn 58.28 Bn 1.37 Bn -
4 Moderna 57.89 Bn 52.75 Bn 52.00 Mn -
5 Revolution Medicines 44.02 Bn 44.02 Bn - -
6 BeOne Medicines 39.95 Bn 34.85 Bn 1.53 Bn 17.05 Mn
7 Alnylam Pharmaceuticals 35.49 Bn 32.19 Bn 992.69 Mn -
8 Royalty Pharma 28.43 Bn 27.59 Bn - -
9 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
10 Celldex Therapeutics 3.08 Bn 3.08 Bn -2.57 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2011 12.50 Mn